Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma

The treatment of advanced unresectable HCC (aHCC) remains a clinical challenge, with limited therapeutic options and poor prognosis. The results of IMbrave150 and HIMALAYA have changed the treatment paradigm for HCC and established immune checkpoint inhibition (ICI), either combined with anti-angiog...

Descripción completa

Detalles Bibliográficos
Autores principales: Foy, Victoria, McNamara, Mairéad G., Valle, Juan W., Lamarca, Angela, Edeline, Julien, Hubner, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529518/
https://www.ncbi.nlm.nih.gov/pubmed/37754543
http://dx.doi.org/10.3390/curroncol30090628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529518/
https://www.ncbi.nlm.nih.gov/pubmed/37754543
http://dx.doi.org/10.3390/curroncol30090628

Ejemplares similares